Three-year EFS for Each Single Drug for S and R Sensitivity Groups
| Drug . | 3-yr EFS . | Log-Rank Test P Value . | |
|---|---|---|---|
| . | S Group . | R Group . | . |
| DNR | 0.728 | 0.624 | .212 |
| ACR | 0.680 | 0.690 | .792 |
| VP16 | 0.726 | 0.592 | .028 |
| L-ASP | 0.721 | 0.631 | .086 |
| THP-ADR | 0.728 | 0.636 | .159 |
| MIT | 0.781 | 0.567 | .009 |
| L-PAM | 0.737 | 0.584 | .074 |
| 4HC | 0.676 | 0.626 | .080 |
| AraC | 0.700 | 0.647 | .471 |
| MTX | 0.757 | 0.665 | .494 |
| BLM | 0.865 | 0.635 | .049 |
| VCR | 0.821 | 0.596 | .002 |
| VLB | 0.706 | 0.667 | .582 |
| MMC | 0.801 | 0.609 | .185 |
| Pred | 0.755 | 0.595 | .028 |
| Dex | 0.762 | 0.606 | .158 |
| Drug . | 3-yr EFS . | Log-Rank Test P Value . | |
|---|---|---|---|
| . | S Group . | R Group . | . |
| DNR | 0.728 | 0.624 | .212 |
| ACR | 0.680 | 0.690 | .792 |
| VP16 | 0.726 | 0.592 | .028 |
| L-ASP | 0.721 | 0.631 | .086 |
| THP-ADR | 0.728 | 0.636 | .159 |
| MIT | 0.781 | 0.567 | .009 |
| L-PAM | 0.737 | 0.584 | .074 |
| 4HC | 0.676 | 0.626 | .080 |
| AraC | 0.700 | 0.647 | .471 |
| MTX | 0.757 | 0.665 | .494 |
| BLM | 0.865 | 0.635 | .049 |
| VCR | 0.821 | 0.596 | .002 |
| VLB | 0.706 | 0.667 | .582 |
| MMC | 0.801 | 0.609 | .185 |
| Pred | 0.755 | 0.595 | .028 |
| Dex | 0.762 | 0.606 | .158 |
S group patients have lower sensitivity than median concentration for each drug. R group patients have median or higher sensitivity than median concentration for each drug.